The Pharma Data

AUGUST 3, 2021

Revenue in the second quarter of 2021 increased 23 percent, driven by volume growth of 22 percent. – Revenue from all key products grew in the quarter and 2021 year-to-date. . – Revenue from all key products grew in the quarter and 2021 year-to-date. – 2021 EPS guidance updated to be in the range of $6.73

Production 52

Production Marketing Research Government 52

Drug Discovery World

SEPTEMBER 6, 2022

Unsurprisingly, oncology remains the biggest focus for cell and gene therapy developers, accounting for 52% of clinical activity in 2021, according to ARM’s Regenerative Medicine: Disrupting the Status Quo report. Cancer is king . Despite this the industry is still expanding. New indications .

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

Drug Discovery World

APRIL 12, 2023

Testing new modality drugs poses additional challenges The drug development pipeline is no longer predominantly composed of small molecule drugs. 2021) 6 evaluated the role of SPTBN1 in diet-induced liver diseases and cancer. Drug-induced liver injury (DILI) is the most common cause of acute liver failure in the western world 4.

Drug Development 130

Drug Development Drugs Small Molecule Immune Response 130

Drug Discovery World

JANUARY 20, 2023

Testing new modality drugs poses additional challenges The drug development pipeline is no longer predominantly composed of small molecule drugs. 2021) 6 evaluated the role of SPTBN1 in diet-induced liver diseases and cancer. Drug-induced liver injury (DILI) is the most common cause of acute liver failure in the western world 4.

Drug Development 130

Drug Development Drugs Small Molecule Immune Response 130

The Pharma Data

SEPTEMBER 9, 2020

Immunization of non-human primates (rhesus macaques) with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate that expresses the SARS-CoV-2 spike glycoprotein, resulted in strong anti-viral effects against an infectious SARS-CoV-2 challenge. producing CD8+ T cell responses, which is thought to promote an anti-viral effect.

Vaccine 52

Vaccine RNA Clinical Trials Immune Response 52

Codon

AUGUST 27, 2024

When doctors sequenced the DNA and RNA found in Alice’s blood and synovial fluid—the liquid that surrounds and lubricates joints—they found abnormally low levels of genes encoding iron-storing proteins and high levels of epidermal growth factor receptor RNA.

DNA 84

DNA Hospitals Laboratories Virus 84

The Pharma Data

JUNE 26, 2021

BNT111 is the lead product candidate from BioNTech’s FixVac platform that targets a fixed combination of mRNA-encoded, tumor-associated antigens with the objective of triggering a strong and precise immune response against cancer and is fully owned by BioNTech. These results were published in Nature in July 2020.

Clinical Trials 52

Clinical Trials Trials Immune Response Vaccine 52